Biotechnology - Pharmaceutical


Current filters:


Popular Filters

76 to 100 of 869 results

Health Canada backs pediatric Humira for Crohn's


US drugmaker AbbVie (NYSE: ABBV) says that Health Canada has approved its blockbuster rheumatoid arthritis…

AbbVieBiotechnologyGastro-intestinalsHumiraNorth AmericaPharmaceuticalRegulation

Nexavar gains FDA priority review for thyroid cancer sNDA


German drug major Bayer (BAYN: DE) and partner Onyx Pharmaceuticals (Nasdaq: ONXX), which has just agreed…

BayerBiotechnologyNexavarNorth AmericaOncologyOnyx PharmaceuticalsPharmaceuticalRegulation

New therapies to spur acute myeloid leukemia market growth


Driven by a boost in new therapies entering the market, as well as an increasing number of acute myeloid…

BiotechnologyCyclacel PharmaceuticalsMarkets & MarketingmidostaurinNovartisOncologyPharmaceuticalsapacitabineSunesis Pharmaceuticalsvosaroxin

AstraZeneca nabs Amplimmune for $500 million


In a further bid to expand its ailing research portfolio, Anglo-Swedish drug major AstraZeneca (LSE:…

AmplimmuneAstraZenecaBiotechnologyMergers & AcquisitionsOncologyPharmaceutical

Chiesi expands rare disease portfolio with acquisition


Privately-owned Italian drugmaker Chiesi Group has signed, through its UK affiliate, a definitive agreement…

BiotechnologyChiesi FarmaceuticiLamazymMergers & AcquisitionsPharmaceuticalRare diseasesZymenex

Shire and Santaris extend strategic alliance


Danish privately held clinical-stage biopharmaceutical company Santaris Pharma says that its long term…

BiotechnologyLicensingPharmaceuticalRare diseasesResearchSantaris PharmaShire

Sirona Biochem signs LoI with leading Chinese diabetes company


Canada's Sirona Biotech (TSX VENTURE:SBM) has signed a letter of intent to provide an exclusive license…

Asia-PacificBiotechnologyDiabetesFosun PharmaLicensingPharmaceuticalSGLT2Sirona BiochemWanbang Pharma

Bayer gets Japanese OK for GI stromal tumors drug


German drug major Bayer (BAYN: DE) has received approval from the Ministry of Health, Labor and Welfare…


Eylea captures quarter of wet-AMD patient share in USA, surpassing Lucentis


Retinal specialists/general ophthalmologists in the USA surveyed by BioTrends Research, a unit of health…

BiotechnologyMarkets & MarketingNorth AmericaOphthalmicsPharmaceutical

Eli Lilly's investigational sNSCLC drug meets Ph III endpoint


US drug major Eli Lilly's (NYSE: LLY) shares rose nearly 4% to $56.21in pre-market trading when the company…

BiotechnologyBristol-Myers SquibbEli LillynecitumumabOncologyPharmaceuticalResearch

Amgen's US deal with Servier cleared


USA-based Amgen (Nasdaq: AMGN), the world's leading independent biotech firm, and privately-held French…

AmgenBiotechnologyCardio-vascularLicensingNorth AmericaPharmaceuticalProcoralanServier

Dainippon Sumitomo establishes regenerative and cellular medicine office


Japanese drug major Dainippon Sumitomo Pharma (TYO: 4506) says that it has set up the Regenerative &…

Asia-PacificBiotechnologyDainippon Sumitomo PharmaPharmaceuticalProductionResearch

GSK launches $50 million VC fund to invest in pioneering bioelectronic medicines and technologies


UK pharma giant GlaxoSmithKline (LSE: GSK) today (August 8) announced the launch of Action Potential…

BiotechnologyFinancialGlaxoSmithKlinePharmaceuticalResearchSetPoint Medical

Cancer and orphan drugs drive increase in US NME approvals


Until 2010, the number of New Molecular Entities (NMEs) approved by the US Food and Drug Administration…

BiotechnologyNorth AmericaPharmaceuticalRegulation

AHF claims victory over FDA in HIV prevention drug case


The USA-based AIDS Healthcare Foundation (AHF) says it won a key legal victory in a push for drug safety…

Anti-viralsBiotechnologyGilead SciencesLegalNorth AmericaPharmaceuticalRegulationTruvada

Orexigen updates on obesity drug filing plans


US biopharma company Orexigen Therapeutics (Nasdaq: OREX) yesterday (August 7) announced its plan to…

BiotechnologyContraveEuropeFinancialMetabolicsOrexigen TherapeuticsPharmaceuticalRegulation

New Zealand to widen access for type 1 and type 3 Gaucher disease drug


New Zealand's Pharmaceutical Management Agency PHARMAC has announced the approval of a proposal to widen…

Asia-PacificBiotechnologyCerezymeGenzymePharmaceuticalRare diseasesRegulationSanofi

Novartis enters into a collaboration for Il-17 inhibitor


US biotech firm Ensemble Therapeutics, a company developing Ensemblins, a novel class of small molecule…

BiotechnologyEnsemble TherapeuticsImmunologicalsInflammatory diseasesLicensingNovartisPharmaceutical

Eylea meets primary endpoint in Ph III DME study


German pharma major Bayer (BAYN: DE) revealed this morning (August 6) that, in the Phase III VIVID-DME…


UK NICE guidance says breast cancer drug Perjeta not value for money


The UK's National Health Service (NHS) is to be advised that it should not routinely provide Swiss drug…


July a strong month for life sciences IPOs and M&A


The life sciences initial public offering (IPO) market continued to heat up in July as six life sciences…

BiotechnologyCubist PharmaceuticalsFinancialMergers & AcquisitionsPerrigoPharmaceuticalRoche

Aegerion gains European approval for rare disease drug


The European Commission has approved US biopharma company Aegerion Pharmaceuticals' (Nasdaq: AEGR) Lojuxta…

Aegerion PharmaceuticalsBiotechnologyCardio-vascularEuropeJuxtapidKynamroLojuxtalomitapidePharmaceuticalRare diseasesRegulation

Pharma associations strongly support Senate bill on FDA User Fees sequestration exemptions


In the USA last week, Mark Pryor (Democrat, Arkansas), chairman of the Senate Appropriations Subcommittee…

BiotechnologyFinancialGenericsLegalNorth AmericaPharmaceuticalPolitics

Germany's IQWiG confirms Jetrea's added value for VMT patients


Belgian biopharma company ThromboGenics (Euronext Brussels: THR) announced today (August 2) that the…


76 to 100 of 869 results

Back to top